SCHEMBL14416655

SCHEMBL14416655

CCNc1ccc(CC)cn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 2/20 0.53
ADRA2A P08913 2/20 0.50
ADRA2B P18089 2/20 0.50
ADRA2C P18825 2/20 0.50
PIK3CD O00329 1/20 0.43
PIP5K1C O60331 1/20 0.43
PIK3CA P42336 1/20 0.43
PIK3CB P42338 1/20 0.43
PI4KA P42356 1/20 0.43
PIK3CG P48736 1/20 0.43
PI4KB Q9UBF8 1/20 0.43
KDM4E B2RXH2 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
DEGS1 O15121 1/20 0.41
NPC1 O15118 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPK1 P28482 1/20 0.41
SYK P43405 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12327198 0.84 HCAR3 (0.56) HCAR3ADRA2AADRA2BADRA2CKDM4E
SCHEMBL12693710 0.81 HCAR3 (0.45) HCAR3ADRA2AADRA2BADRA2CKDM4E
SCHEMBL21017439 0.81 HCAR3 (0.47) HCAR3ADRA2AADRA2BADRA2CPIK3CD
SCHEMBL14845825 0.81 HCAR3 (0.55) HCAR3KDM4EL3MBTL1DEGS1NPC1
SCHEMBL12020150 0.81 HCAR3 (0.46) HCAR3PIK3CAKDM4EL3MBTL1DEGS1
SCHEMBL13662122 0.80 FABP1 (0.56) KDM4ENPC1SMN1; SMN2ALDH1A1MAPK1
SCHEMBL22606744 0.80 HCAR3 (0.54) HCAR3ADRA2AADRA2BADRA2CKDM4E
SCHEMBL17409798 0.80 KDM4E (0.40) HCAR3ADRA2AADRA2BADRA2CKDM4E
SCHEMBL406014 0.79 KDM4E (0.47) ADRA2AADRA2BADRA2CKDM4EL3MBTL1
SCHEMBL14416656 0.78 HCAR3 (0.57) HCAR3KDM4EDEGS1ALDH1A1SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20130157996-A1 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2013-06-20 US disclosed
US-7271270-B2 High affinity small molecule C5a receptor modulators NEUROGEN CORPORATION (US) 2007-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 HCAR3 1121/4885ADRA2A 1109/4885ADRA2B 3041/4885
US-20130157996-A1 TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS TRPM8, TRPM7, TRPM5 HCAR3 788/4885ADRA2A 604/4885ADRA2B 1164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.